Advertisement

Respiratory Disorders

  • Martin L Engman
  • Rodney C Richie
Chapter
  • 45 Downloads

Abstract

Lung disorders are common in the general population. Chronic bronchitis affects 10–25% of the USA population, asthma 5%, and emphysema about 3%. In 1992 these chronic obstructive pulmonary diseases were the fourth leading cause of mortality in the USA, accounting for more than 91,800 deaths.1 Pneumonia is the sixth leading cause of death in the USA.2 It has been estimated that 2–4 million cases of community-acquired pneumonia occur in the USA each year, and that as many as 20% of these require hospitalization. Occupational lung disease, cystic fibrosis, hypersensitivity pneumonitis and other respiratory disorders affect many others. Accordingly, life insurance applications from persons with a variety of respiratory disorders are frequently encountered, and the underwriter and medical consultant are called on with some regularity to render assessments of the mortality risk associated with various pulmonary impairments.

Keywords

Obstructive Sleep Apnea Sleep Apnea Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Chronic Bronchitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Kochanek KD, Judson BL. Advance report of final mortality statistics, 1992. Monthly Vital Statistics Report 1995; 43: 1–73, 1995.Google Scholar
  2. 2.
    Campbell CD. Overview of community acquired pneumonia. Med Clin North Am 1994; 78: 1035–48.PubMedCrossRefGoogle Scholar
  3. 3.
    Anthonison NR. Home oxygen therapy in chronic obstructive pulmonary disease. Clin Chest Med 1986; 7: 673–8.Google Scholar
  4. 4.
    Clini E et al. Long-term home care programmes may reduce hospital admissions in COPD with chronic hypercapnia. Minerva Anesthesiologica 1996; 62(3): 57–64.Google Scholar
  5. 5.
    Dallari R et al. Predictors of survival in subjects with chronic obstructive pulmonary disease treated with long-term oxygen therapy. Respiration 1994; 1(1): 8–13.Google Scholar
  6. 6.
    Strom K, Boman G: Long-term oxygen therapy in parenchymal lung disease: an analysis of survival. Eur RespirJ 1993; 8: 1264–70.Google Scholar
  7. 7.
    American Medical Association Guide to the Evaluation of Permanent Impairment. 4th edn. American Medical Association, 1993; 5, 162.Google Scholar
  8. 8.
    Kory RC. The Veterans Administration Army Cooperative study of pulmonary function. I. Clinical spirometry in normal men. Am J Med 1961; 3: 243–58.CrossRefGoogle Scholar
  9. 9.
    Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis 1971; 103: 57–67.PubMedGoogle Scholar
  10. 10.
    Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659–64.PubMedGoogle Scholar
  11. 11.
    Knudson RJ et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127: 725–34.PubMedGoogle Scholar
  12. 12.
    Enright PL et al. Spirometry reference values for men and women 65 to 85 years of age: Cardiovascular Health Study. Am Rev Respir Dis 1993; 147: 125–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Petty TL. It’s never too late to stop smoking. JAMA 1993; 269: 2785.PubMedCrossRefGoogle Scholar
  14. 14.
    Bang KM et al. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest 1993; 103: 536–40.PubMedCrossRefGoogle Scholar
  15. 15.
    Lange P et al. Ventilatory function impairment and risk of cardiovascular death and of fatal or non-fatal myocardial infarction. Eur Respir J 1991; 4: 1080–7.PubMedGoogle Scholar
  16. 16.
    Peto R et al. The relevance in adults of air-flow obstruction, but not of mucous hypersecretion, to mortality from chroniclung disease. Am Rev Respair Dis 1983; 128: 491–500.CrossRefGoogle Scholar
  17. 17.
    Sorlie PD, Kannel WB, O’Connor G. Mortality associated with respiratory function and symptoms of advanced age. Am Rev Respir Dis 1989; 140: 379–84.PubMedCrossRefGoogle Scholar
  18. 18.
    Beaty TH et al. Effects of pulmonary function on mortality. J Chron Dis 1985; 38: 703–10.PubMedCrossRefGoogle Scholar
  19. 19.
    Tockman MS et al. Rapid decline in FEV1, a new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med 1995; 151: 390–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Kuller L et al. Relation of forced expiratory volume in one second (FEV1) to lung cancer mortality in the multiple risk factorintervention trial. Am J Epidemiol 1990; 132: 265–72.PubMedCrossRefGoogle Scholar
  21. 21.
    Pinkham A. Personal communication. Lincoln National Reinsurance, 1996.Google Scholar
  22. 22.
    Pare P. Conference summary: asthma structure and function. Chest 1995; 107 (suppl): 163S-9S.CrossRefGoogle Scholar
  23. 23.
    Bone RC. Goals in asthma management, a step-care approach. Chest 1996; 109: 1056–65.PubMedCrossRefGoogle Scholar
  24. 24.
    National Asthma Education Program Expert Panel Report: guidelines for the diagnosis and management of asthma. 1991 USDHHS (PHS) Publication number 1991–3042.Google Scholar
  25. 25.
    Woolcock AJ. Asthma. In: Murray JF, Nadel JA (eds). Textbook of Respiratory Medicine. 2nd edn. Philadelphia: WB Saunders Company, 1994; 1288–91.Google Scholar
  26. 26.
    Weiss ST. The origins of childhood asthma. Monaldi Archives for Chest Disease 1994; 49: 154–8.PubMedGoogle Scholar
  27. 27.
    Byrd JC. Environmental tobacco smoke. Med Clin North Am 1992; 76: 377–98.PubMedCrossRefGoogle Scholar
  28. 28.
    Kivity S et al. The characteristics of bronchial asthma among a young adult population. Chest 1995; 108: 24–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Banner AS. The increase in asthma prevalence. Chest 1995; 108: 301–2.PubMedCrossRefGoogle Scholar
  30. 30.
    Wobig EK, Rosen R. Death from asthma: rare but real. J Emerg Med 1996: 223–40.Google Scholar
  31. 31.
    Weiss KB, Gergen PJ, Wagener DK. Breathing better or wheezing worse: the changing epidemiology of asthma morbidity and mortality. Ann Rev Publ Health 1993; 14: 491–513.CrossRefGoogle Scholar
  32. 32.
    Taylor DR, Sears MR, Cockcroft DW. The beta-agonist controversy. Med Clin North Am 1996; 80: 719–43.PubMedCrossRefGoogle Scholar
  33. 33.
    Leikauf GD et al. Evalauation of a possible association of urban air toxins and asthma. Environ Health Perspect 1995; 103 (suppl 6): 253–71.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Koren HS. Associations between criteria air pollutants and asthma. Environ Health Perspect 1995; 103 (suppl 6): 235–42.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Weiss K, Wagener DK. Changing patterns of asthma mortality: identifying target populations at high risk. JAMA 1990; 264: 1683–7.PubMedCrossRefGoogle Scholar
  36. 36.
    De Palo VA et al. Demographic influences on asthma hospital admission rates in New York City. Chest 1994; 106:447–51.PubMedCrossRefGoogle Scholar
  37. 37.
    Gottlieb DJ, Beiser AS, O’Connor GT. Poverty, race and medication use are correlates of asthma hospitalization rates, a small area analysis in Boston. Chest 1995; 108: 28–35.PubMedCrossRefGoogle Scholar
  38. 38.
    Greenberger PA, Miller TP, Lifschultz B. Circumstances surrounding deaths from asthma in Cook county (Chicago), Illinois. Allergy Proc 1993; 14: 321–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Ulrik CS, Frederiksen J. Mortality and markers of risk of asthma death among 1075 outpatients with asthma. Chest 1995; 108: 10–15.PubMedCrossRefGoogle Scholar
  40. 40.
    Silverstein MD et al. Long-term survival of a cohort of community residents with asthma. N Engl J Med 1994; 331: 1573–41.CrossRefGoogle Scholar
  41. 41.
    Marquette CH et al. Long-term prognosis of near-fatal asthma: a 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis 1992; 146: 76–81.PubMedCrossRefGoogle Scholar
  42. 42.
    Medical Impairment Study 1983. Vol 1. Boston: Society of Actuaries and Association of Life Insurance Medical Directors of America, 1986; 74–5.Google Scholar
  43. 43.
    Fessel M. Mortality of policyholders suffering from chronic obstructive pulmonary disease. 36th meeting of Swiss Life Assurance Medical Directors, Zurich, 1984. Cited in: Mills RJ, Brackenridge RDC. Respiratory disorders. In: Brackenridge RDC, Elder WJ (eds). Medical Selection of Life Risks. 3rd edn. New York: Stockton Press, 1992; 489.Google Scholar
  44. 44.
    Pinkham A. Personal communication. Lincoln National Reinsurance, 1993.Google Scholar
  45. 45.
    Woolcock AJ, Jenkins CR. Assessment of bronchial responsiveness as a guide to prognosis and therapy in asthma. Med Clin North Am 1990; 74: 753–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Picado. J Asthma 1989; 26: 231–6.Google Scholar
  47. 47.
    Marquette CH et al. Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis 1992; 146(1): 76–81.PubMedCrossRefGoogle Scholar
  48. 48.
    Ernst P et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA 1992; 268: 3462–4.PubMedCrossRefGoogle Scholar
  49. 49.
    Bond WS. Toxic reactions and side effects of glucocorticoids in man. Am J Hosp Pharmacy 1977; 34: 479–85.Google Scholar
  50. 50.
    USA Public Health Service: Smoking and Health. A report of the Advisory Committee to the Surgeon General of the Public Health Service. USA Dept of Health, Education, and Welfare, Public Health Service, Center for Disease Control. PHS (PN) 1103, 1964.Google Scholar
  51. 51.
    USA Dept of Health, Education, and Welfare. The Health Consequences of Smoking. Chronic Obstructive Lung Disease. USA Department of Health and Human Services, Public Health Service, Office of Smoking. Rockville, MD 20857, DHHS (PHS) 84–50205, 1984.Google Scholar
  52. 52.
    Sherman CB. The health consequences of smoking. Med Clin North Am 1992; 76: 355–75.PubMedCrossRefGoogle Scholar
  53. 53.
    Dockery DW et al. Cumulative and reversible effects of lifetime smoking on simple tests of lung function in adults. Am Rev Respir Dis 1988; 137: 286–92.PubMedCrossRefGoogle Scholar
  54. 54.
    Burrows B et al. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 1917; 115: 195–205.Google Scholar
  55. 55.
    Beck GJ, Doyle CA, Schachter EN. Smoking and lung function. Am Rev Respir Dis 1981; 123: 149–55.PubMedGoogle Scholar
  56. 56.
    Burchfiel CM et al. Effects of smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 1995; 151: 1778–85.PubMedCrossRefGoogle Scholar
  57. 57.
    Snider GL, Faling LJ, Rennard SJ. Chronic bronchitis and emphysema. In: Murray JF, Nadel JA (eds). Textbook of Respiratory Medicine. 2nd edn Philadelphia: WB Saunders Company, 1994: 1342–3.Google Scholar
  58. 58.
    Stanescu D et al. Identification of smokers susceptible to development of chronic airflow limitation: a 13-year follow-up. Chest. 1998; 114(2): 416–25.PubMedCrossRefGoogle Scholar
  59. 59.
    Thun MJ, Day-Lally CA, Calle EE Excess mortality among cigarette smokers: changes in a 20 year interval. Am J Public Health 1995; 85: 1223–30.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Snider GL, Faling LJ, Rennard SJ. Chronic bronchitis and emphysema. In: Murray JF, Nadel JA (eds). Textbook of Respiratory Medicine. 2nd edn Philadelphia: WB Saunders Company, 1994; 1344.Google Scholar
  61. 61.
    Eriksson S. A 30 year perspective on alpha 1 antitrypsin deficiency. Chest 1996; 110: 237s–242s.PubMedCrossRefGoogle Scholar
  62. 62.
    Clausen JL. The diagnosis of emphysema, chronic bronchitis, and asthma. Clin Chest Med 1990; 11: 405–16.PubMedGoogle Scholar
  63. 63.
    Burrows B. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987; 317: 1309–14.PubMedCrossRefGoogle Scholar
  64. 64.
    Butz RH. Mortality associated with chronic pulmonary disease. J Insur Med 1988; 20: 46–7.Google Scholar
  65. 65.
    Krzyzanowski M, Jedrychowski W, Wysocki M. Factors associated with the change in ventilatory function and the development of chronic obstructive pulmonary disease in a 13-year follow-up of the Cracow Study. Am Rev Respir Dis 1986; 134: 1011–19.PubMedCrossRefGoogle Scholar
  66. 66.
    Speizer FE et al. Chronic obstructive pulmonary disease mortality in six USA cities. American Review of Respiratory Disease 1089, 140: S49–55.CrossRefGoogle Scholar
  67. 67.
    Medical Impairment Study 1983. Vol 1. Boston: Society of Actuaries and Association of Life Insurance Medical Directors of America, 1986; 76–7.Google Scholar
  68. 68.
    Fessel M. Mortality of policyholders suffering from chronic obstructive pulmonary disease. 36th meeting of Swiss Life Assurance Medical Directors, Zurich, 1984. Cited in: Mills RJ, Brackenridge RDC. Respiratory disorders. In: Brackenridge RDC, Elder WJ (eds). Medical Selection of Life Risks. 3rd edn. New York: Stockton Press, 1992; 485.Google Scholar
  69. 69.
    Clarke RD. Mortality of impaired lives. J Inst Actuar. Cited in: Mills RJ, Brackenridge RDC. Respiratory disorders. In: Brackenridge RDC, Elder WJ (eds). Medical Selection of Life Risks. 3rd edn. New York: Stockton Press, 1992; 485.Google Scholar
  70. 70.
    Fessel M. Chronic obstructive pulmonary disease in European insureds. J Insur Med 1991; 23: 38–9.PubMedGoogle Scholar
  71. 71.
    National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059–73.CrossRefGoogle Scholar
  72. 72.
    Yusen RD et al. A prospective evaluation of lung volume reduction surgery in 200 consecutive patients. Chest. 2003; 123(4): 975–7.CrossRefGoogle Scholar
  73. 73.
    Luce JM. Bronchiectasis. In: Murray JF, Nadel JA (eds). Textbook of Respiratory Medicine 2nd edn. Philadelphia: WB Saunders Company, 1994; 1402.Google Scholar
  74. 74.
    Selman-Lama M, Padilla RP. Airflow obstruction and airway lesions in hypersensitivity pneumonitis. Clin Chest Med 1993; 14: 699–714.PubMedGoogle Scholar
  75. 75.
    Epier GR et al. Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985; 312: 152–8.CrossRefGoogle Scholar
  76. 76.
    Wells AU, du Bois RM. Bronchiolitis is association with connective tissue disorders. Clin Chest Med 1993; 14: 657–9.Google Scholar
  77. 77.
    Lazarus SC. Disorders of the intrathoracic airways. In: Murray JF, Nadel JA (eds). Textbook of Respiratory Medicine. 2nd edn Philadelphia: WB Saunders Company, 1994; 1476.Google Scholar
  78. 78.
    Clark JG et al. Obstructive lung disease after allogenic marrow transplantation. Ann Intern Med 1989; 111: 368–76.PubMedCrossRefGoogle Scholar
  79. 79.
    Fraser RG et al. Diagnosis of Diseases of the Chest. 3rd edn. Philadelphia: WB Saunders Company, 1990; 2212.Google Scholar
  80. 80.
    Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 1995; 26: 777–807.CrossRefGoogle Scholar
  81. 81.
    Stern RC. The diagnosis of cystic fibrosis. New Engl J Med 1997; 336: 487–91.PubMedCrossRefGoogle Scholar
  82. 82.
    Tsui L. The cystic fibrosis transmembrane conductance regulator gene. Am J Respir Crit Care Med 1995; 151: S47–S53.PubMedCrossRefGoogle Scholar
  83. 83.
    Egan TM, Detterbeck FC, Mill MR. Improved results of lung transplantation for patients with cystic fibrosis. J Thorac Cardiovasc Surg 1995; 109: 224–35.PubMedCrossRefGoogle Scholar
  84. 84.
    Whitehead BF et al. Results of heart-lung transplantation in children with cystic fibrosis. Eur J Cardiothorac Surg 1995; 9: 1–6.PubMedCrossRefGoogle Scholar
  85. 85.
    Frederiksen B et al. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol. 1996; 21: 153–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Holmberg L, Boman G. Pulmonary reactions to nitrofurantoin. 447 cases reported to the Swedish Adverse Drug Reaction Committee 1966–1976. Eur J Respir Dis 1981; 62: 180–9.PubMedGoogle Scholar
  87. 87.
    Sleijfer S. Bleomycin pneumonitis. Chest 2001; 120: 617–24.PubMedCrossRefGoogle Scholar
  88. 88.
    Imokawa S et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000; 32: 373–81.CrossRefGoogle Scholar
  89. 89.
    Martin WJI, Rosenow ECI. Amiodarone pulmonary toxicity. Recognition and pathogenesis. Part 1: Chest 1988; 93: 1067–75. Part 2: Chest 1988; 93: 1242–8.Google Scholar
  90. 90.
    Foucher P, Camus P. Pneumotox. 1977. Available at http://www.pneumotox.com (accessed September 2002).Google Scholar
  91. 91.
    Freemer MM, King Jr TE. Connective Tissue Diseases. In: Interstitial Lung Disease, 4th edn, Ed. MI Schwarz and TE King Jr. BC Decker, London 2003; 535.Google Scholar
  92. 92.
    Black LF, Katz S. Respiratory disease: task force report on problems, research approaches, needs. National Heart and Lung Institute; 1977 DHEW Publication No: NIH77–1248, Washington, DC.Google Scholar
  93. 93.
    Douglas WW et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164: 1182–5.PubMedCrossRefGoogle Scholar
  94. 94.
    Fujita J et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001; 60: 281–3.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Kim DS et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoid Vasc Diffuse Lung Dis 2002; 19: 121–7.Google Scholar
  96. 96.
    Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular disorders. Clin Chest Med 1982; 3: 565–78.Google Scholar
  97. 97.
    Saag KG et al. Rheumatoid arthritis lung disease. Determininants of radiographic and physiologic abnormalities. Arthritis Rheum 1996; 39: 1711–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 2002; 41: 676–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Turner-Warwick M, Evans RC. Pulmonary manifestations of rheumatoid disease. Clin Rheum Dis 1977; 3: 549–64.Google Scholar
  100. 100.
    Hakala M. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung fibrosis. Chest 1988; 93: 114–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Gordon DA, Broder I, Hyland RH. Rheumatoid arthritis. In: Cannon GW, Zimmerman GA, editors. The lung in rheumatic diseases. New York: Marcel Dekker, Inc; 1990; 229.Google Scholar
  102. 102.
    Matthay RA et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 1975; 54: 397–409.PubMedCrossRefGoogle Scholar
  103. 103.
    Haupt HM, More GM, Hutchins GM. The lung in systemic lupus erythematosus: analysis of the pathologic changes in 120 patients. Am J Med 1981; 72: 791–7.CrossRefGoogle Scholar
  104. 104.
    Miller LR, Greenberg SD, McLarty JW. Lupus lung. Chest 1985; 88: 265–9.PubMedCrossRefGoogle Scholar
  105. 105.
    Benisch B, Peison B. The association of lymphocytic interstitial pneumonitis and systemic lupus erythematosus. Mt Sinai J Med 1979; 46: 398–401.PubMedGoogle Scholar
  106. 106.
    Yum MN et al. Pseudolymphoma of the lung in a patient with systemic lupus erythematosus. Am J Med 1979; 66: 172–6.PubMedCrossRefGoogle Scholar
  107. 107.
    Milligan DW, Chang JG. Systemic lupus erythematosus and lymphoma. Acta Haematol 1980; 64: 109–10.PubMedCrossRefGoogle Scholar
  108. 108.
    Yokoi T et al. Pulmonary hypertension associated with systemic lupus erythematosus: predominantly thrombotic arteriopathy accompanied by plexiform lesions. Arch Pathol Lab Med 1998; 122: 467–70.PubMedGoogle Scholar
  109. 109.
    Belmont HM et al. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum 1994; 37: 376–83.PubMedCrossRefGoogle Scholar
  110. 110.
    Thompson PJ et al. Shrinking lungs, diaphragmatic dysfunction, and systemic lupus erythematosus. Am Rev Respir Dis 1985; 132: 926–8.PubMedGoogle Scholar
  111. 111.
    Walz-Leblanc BA et al. The ‘shrinking lungs syndrome’ in systemic lupus erythematosus — improvement with corticosteroid therapy. J Rheumatol 1992; 19: 1970–2.PubMedGoogle Scholar
  112. 112.
    Warrington KJ, Moder KG, Brutinel WM. The shrinking lungs syndrome in systemic lupus erythematosus. Mayo Clin Proc 2000; 75: 467–72.PubMedCrossRefGoogle Scholar
  113. 113.
    Kurland LT et al. Epidemiologie features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus. Mayo Clin Proc 1969; 44: 649–63.PubMedGoogle Scholar
  114. 114.
    Scussel-Lonzetti L et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 154–67.PubMedCrossRefGoogle Scholar
  115. 115.
    LeRoy EC. Scleroderma (systemic sclerosis). In: Kelley WN, Harris EDJ, Ruddy S, Sledge CB, (eds). Textbook of rheumatology. Philadelphia: W.B. Saunders; 1985; 1183.Google Scholar
  116. 116.
    Ferri C et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine (Baltimore) 2002; 81: 139–53.PubMedCrossRefGoogle Scholar
  117. 117.
    Medsger TAJ. Progressive systemic sclerosis. Clin Rheum Dis 1983; 8: 655–70.Google Scholar
  118. 118.
    Peters GM et al. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med 1984; 77: 1027–34.CrossRefGoogle Scholar
  119. 119.
    Douglas WW et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164: 1182–5.PubMedCrossRefGoogle Scholar
  120. 120.
    Nakajima H et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen disease. J Rheumatol 2000; 27: 1164–70.PubMedGoogle Scholar
  121. 121.
    Kubo M et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford) 2000; 39: 632–6.PubMedCrossRefGoogle Scholar
  122. 122.
    Manthorpe R et al. Sjögren’s syndrome. A review with emphasis on immunological features. Allergy 1981; 36: 139–53.PubMedCrossRefGoogle Scholar
  123. 123.
    Lahdensuo A, Korpela M. Pulmonary findings in patients with primary Sjögren’s syndrome. Chest 1995; 108: 316–9.PubMedCrossRefGoogle Scholar
  124. 124.
    Rosenstock L, Cullen MR. Textbook of Clinical Occupational and Environmental Medicine. Philadelphia: WB Saunders Company, 1994; 195.Google Scholar
  125. 125.
    Rom WN (ed). Environmental and Occupational Medicine. 2nd edn. Boston: Little, Brown and Co, 1992, 1–1493.Google Scholar
  126. 126.
    Murray JF, Nadel JA. Textbook of Respiratory Medicine. 2nd edn. Philadelphia: WB Saunders Company, 1994; 1977.Google Scholar
  127. 127.
    Nicholson WJ, Perkel G, Selikoff IJ. Occupational exposure to asbestos: population at risk and projected mortality, 1980–2030. Am J Ind Med 1982; 3:259–311.PubMedCrossRefGoogle Scholar
  128. 128.
    Copes R, Thomas D, Becklake MR. Temporal patterns of exposure and nonmalignant pulmonary abnormality in Quebec chrysotile workers. Arch Environ Health 1985; 40: 80–87.PubMedCrossRefGoogle Scholar
  129. 129.
    Dreessen WC et al. A study of asbestosis in the asbestos textile industry. Public Health Bulletin No. 241. USA Govt Printing Office, Washington, 1938.Google Scholar
  130. 130.
    Murray JF, Nadel JA (eds). Textbook of Respiratory Medicine. 2nd edn. Philadelphia: WB Saunders Company, 1994; 1962.Google Scholar
  131. 131.
    Rosenstock L, Cullen MR (eds). Textbook of Clinical Occupational and Environmental Medicine. Philadelphia: WB Saunders Company, 1994; 265.Google Scholar
  132. 132.
    Kleinerman J. Pathology standards for coal-workers’ pneumoconiosis. Report of Pneumoconiosis Committee of the College of American Pathologists. Arch Pathol Lab Med 1979; 103: 375–85.Google Scholar
  133. 133.
    Rom WN. Basic mechanisms leading to focal emphysema in coal workers’ pneumoconiosis. Environ Res 1990; 53: 16–28.PubMedCrossRefGoogle Scholar
  134. 134.
    USA Dept of Health and Human Services. Work-Related Lung Disease Surveillance Report. Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health Publication No. 91–113, 1991; 78.Google Scholar
  135. 135.
    Morgan WKC, Seaton A. Occupational Lung Diseases. 2nd edn. Philadelphia: WB Saunders Company, 1984; 334.Google Scholar
  136. 136.
    Pneumoconiosis redefined (editorial). BMJ 1972; 2: 552.Google Scholar
  137. 137.
    Attfield MD, Seixas NS. Prevalence of pneumoconiosis and its relationship to dust exposure in a cohort of USA butuminous coal miners and ex-miners. Am J Ind Med 1995; 27: 137–51.PubMedCrossRefGoogle Scholar
  138. 138.
    Kuempel ED et al. Exposure-response analysis of mortality among coal miners in the United States. Am J Ind Med 1995; 28: 167–84.PubMedCrossRefGoogle Scholar
  139. 139.
    Fraser RG et al. Diagnosis of Diseases of the Chest. 3rd edn. Philadelphia: WB Saunders Company, 1990; 2611.Google Scholar
  140. 140.
    Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336: 1224–35.PubMedCrossRefGoogle Scholar
  141. 141.
    Fanburg BL, Lazarus DS. Sarcoidosis. In: Murray JF, Nadel JA (eds). Textbook of Respiratory Medicine. 2nd edn. Philadelphia: WB Saunders Company, 1994; 1873–88.Google Scholar
  142. 142.
    Siltzbach LE et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974; 57: 847–52.PubMedCrossRefGoogle Scholar
  143. 143.
    Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest 1993: 253–8.CrossRefGoogle Scholar
  144. 144.
    Zajicek JP et al Central nervos system sarcoidosis-diagnosis and management. QJ Med 1999;92: 103–117.CrossRefGoogle Scholar
  145. 145.
    James DG. Granulomatous liver disease. In: Schiff L, Schiff ER (eds). Diseases of the Liver. 7th edn. Philadelphia: JB Lippincott Company, 1993; 1500.Google Scholar
  146. 146.
    Disease of the Liver and Biliary System. 9th edn. London: Blackwell Scientific Publications, 1993; 463.Google Scholar
  147. 147.
    Sharma OP. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis 1993; 147: 1598–1600.PubMedCrossRefGoogle Scholar
  148. 148.
    Fraser RG et al. Diagnosis of Diseases of the Chest. 3rd edn. Philadelphia: WB Saunders Company, 1990; 2646.Google Scholar
  149. 149.
    Carrington C, Gaensler E, Coutu R et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298: 801.PubMedCrossRefGoogle Scholar
  150. 150.
    Panos R et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88: 396.PubMedCrossRefGoogle Scholar
  151. 151.
    Kondoh Y et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993; 103: 1808.PubMedCrossRefGoogle Scholar
  152. 152.
    Akira M et al. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 1997; 168: 79.PubMedCrossRefGoogle Scholar
  153. 153.
    Moon J et al. Clinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease. Thorax 1999; 54: 1009.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Olson J, Colby T, Elliott C. Hamman-Rich syndrome revisited. Mayo Clin Proc 1990; 65: 1538.PubMedCrossRefGoogle Scholar
  155. 155.
    Katzenstein AL, Myers JL, Mazur MT. Acute interstitial pneumonia. A clinicopathologic, ultra-structural and cell kinetic study. Am J Surg Pathol 1986; 10: 256.PubMedCrossRefGoogle Scholar
  156. 156.
    Daniil ZD et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160: 899.PubMedCrossRefGoogle Scholar
  157. 157.
    Nicholson AG et al. The prognostic significance of the histological pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162: 2213.PubMedCrossRefGoogle Scholar
  158. 158.
    Travis W et al. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns. Survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000; 24: 19.PubMedCrossRefGoogle Scholar
  159. 159.
    McHugh LG et al. Recovery of function in survivors of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1994; 150: 90–4.PubMedCrossRefGoogle Scholar
  160. 160.
    Peters J et al. Clinical determinants of abnormalities in pulmonary function in survivors of the adult respiratory distress syndrome. Am Rev Respir Dis 1989; 139: 1163–8.PubMedCrossRefGoogle Scholar
  161. 161.
    Elliott CG. Pulmonary sequelae in survivors of the adult respiratory distress syndrome. Clin Chest Med 1990; 11: 789–800.PubMedGoogle Scholar
  162. 162.
    Zapol WM et al. Pulmonary fibrosis in severe acute respiratory failure. Am Rev Respir Dis 1979; 119:547–55.PubMedGoogle Scholar
  163. 163.
    Wang BM et al. Diagnosing pulmonary alveolar proteinosis. Chest 1997; 111: 460–6.PubMedCrossRefGoogle Scholar
  164. 164.
    Wasserman K, Mason GR. Pulmonary alveolar proteinosis. In: Murray JF, Nadel JA (eds). Textbook of Respiratory Medicine Philadelphia: WB. Saunders Company, 1994; 1933–46.Google Scholar
  165. 165.
    Perez-Padilla R et al. Mortality in Mexican patients with chronic pigeon breeder’s lung compared with those with usual interstitial pneumonia. Am Rev Respir Dis 1993; 148: 49–53.PubMedCrossRefGoogle Scholar
  166. 166.
    Schwarz MI, Cherniak RM, King TE. Diffuse alveolar hemorrhage and other rare infiltrative disorders. In: Murray JF, Nadel JA (eds). Textbook of Respiratory Medicine. 2nd edn. Philadelphia: WB Saunders Company, 1994; 1899.Google Scholar
  167. 167.
    Matteson EL et al. Long-term survival of patients with Wegener’s granulomatosis from the American College of Rheumatology Wegener’s granulomatosis classification criteria cohort. Am J Med 1996; 101: 129–34.PubMedCrossRefGoogle Scholar
  168. 168.
    Pope-Harmon AL et al. Acute eosinophilic pneumonia. A summary of 15 cases and review of the literature. Medicine 1996; 75(6): 334–42.CrossRefGoogle Scholar
  169. 169.
    Cheon JE et al. Acute eosinophilic pneumonia: radiographic and CT findings in six patients. AJR Am J Roentgenol 1996; 167(5): 1195–9.PubMedCrossRefGoogle Scholar
  170. 170.
    King MA et al. Acute eosinophilic pneumonia: radiologic and clinical features. Radiology 1997; 203(3): 715–19.MathSciNetPubMedCrossRefGoogle Scholar
  171. 171.
    Chumbley LC, Harrison EG, DeRemee RA: Alletgic granulomatosis and angitis. Mayo Clin Proc 1977; 52: 477–84.PubMedGoogle Scholar
  172. 172.
    Fraser RG et al. Diagnosis of Diseases of the Chest. 3rd edn. Philadelphia: WB Saunders Company, 1990; 1826.Google Scholar
  173. 173.
    Butler J, Agostoni P. Cor pulmonale. In: Murray JF, Nadel JA (eds). Textbook of Respiratory Medicine. 2nd edn. Philadelphia: WB Saunders Company, 1994; 1778.Google Scholar
  174. 174.
    Rubin LJ. Pulmonary vascultis and primary pulmonary hypertension. In: Murray JF, Nadel JA (eds). Textbook of Respiratory Medicine. 2nd edn. Philadelphia: WB Saunders Company, 1994; 1693.Google Scholar
  175. 175.
    Abenhaim L et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 336: 609–16.CrossRefGoogle Scholar
  176. 176.
    D’Alonzo G et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991; 115: 343–9.PubMedCrossRefGoogle Scholar
  177. 177.
    American Academy of Sleep Medicine Task Force. Sleep related breathing disorders in adults: Recommendations for syndrome definition and measurement techniques in clinical research. Sleep 1999; 22(5): 667–689.CrossRefGoogle Scholar
  178. 178.
    Guilleminault Stoohs R et al. Upper airway resistance syndrome, nocturnal blood pressure monitoring and borderline hypertension. Chest 1996; 109: 901–8.PubMedCrossRefGoogle Scholar
  179. 179.
    Lombard RM, Zwillich CW. Medical therapy of obstructive sleep apnea. Med Clin N Am 1985; 69(6): 1325.CrossRefGoogle Scholar
  180. 180.
    Bradley TD et al. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis 1985; 131: 835–9.PubMedGoogle Scholar
  181. 181.
    Fletcher EC et al. Long-term cardiopulmonary sequelae in patients with sleep apnea and chronic lung disease. Am Rev Respir Dis 1987; 135: 525–33.PubMedGoogle Scholar
  182. 182.
    Weitzenblum E et al. Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am Rev Respir Dis 1988; 138: 345–59.PubMedCrossRefGoogle Scholar
  183. 183.
    Parish JM, Shepard JW. Cardiovascular effects of sleep disorders. Chest 1990; 97(5): 1220–6.PubMedCrossRefGoogle Scholar
  184. 184.
    Shepard JW. Cardiovascular consequences of obstructive sleep apnea. Clin Chest Med 1992; 13(3): 442–9.MathSciNetGoogle Scholar
  185. 185.
    Hedner J. Nocturnal hypertension — under the cover of darkness. Blood Press 1995; 4: 197–8.PubMedCrossRefGoogle Scholar
  186. 186.
    Noda A et al. Cardiac hypertrophy in obstructive sleep apnea syndrome. Chest 1995; 107: 1538–44.PubMedCrossRefGoogle Scholar
  187. 187.
    Klitzman D, Miller A. Obstructive sleep apnea-syndromes. Mount Sinai J Med 1994; 61:113–21.Google Scholar
  188. 188.
    Findley L, Unverzadt M, Suratt P. Automobile accidents involving patients with obstructive sleep apnea. Am Rev Respir Dis 1988; 138: 337–40.PubMedCrossRefGoogle Scholar
  189. 189.
    Stoohs RA et al. Traffic accidents in commercial long-haul truck drivers: the influence of sleep disordered breathing. Sleep 1994; 17: 619–23.PubMedGoogle Scholar
  190. 190.
    Gonzales-Rothi RJ, Foresman GE, Block AJ. Do patients with sleep apnea die in their sleep? Chest 1988; 94: 531–8.CrossRefGoogle Scholar
  191. 191.
    Partinen M, Jamieson A, Guilleminault C. Long-term outcome for obstructive sleep apnea syndrome patients. Chest 1988; 94: 1200–4.PubMedCrossRefGoogle Scholar
  192. 192.
    He J et al. Mortality in obstructive sleep apnea. Chest 1988; 94: 9–14.PubMedCrossRefGoogle Scholar
  193. 193.
    Lavie P et al. Mortality in sleep apnea patients: a multivariate analysis of risk factors. Sleep 1995; 18(3): 149–57.PubMedCrossRefGoogle Scholar
  194. 194.
    Bliwise DL et al. Sleep apnea and mortality in an aged cohort. Am J Public Health 1988; 78: 544–7.PubMedPubMedCentralCrossRefGoogle Scholar
  195. 195.
    Pollack CP et al. Sleep problems in the community elderly as predictors of death and nursing home placement. J Community Health 1990; 15: 123–35.CrossRefGoogle Scholar
  196. 196.
    Mant A et al. Four-year follow-up of mortality and sleep related respiratory disturbance in non-demented seniors. Sleep 1995; 18(6): 433–8.PubMedCrossRefGoogle Scholar
  197. 197.
    Fleury B et al. Long-term compliance to continuous positive airway pressure therapy (nCPAP) set up during a split night polysomnography. Sleep 1994; 17: 512–15.PubMedCrossRefGoogle Scholar
  198. 198.
    Hoffstein V et al. Treatment of obstructive sleep apnea with nasal continuous positive airway pressure. Am Rev Respir Dis 1992; 145: 841–5.PubMedCrossRefGoogle Scholar
  199. 199.
    Brackenridge RDC. Respiratory system diseases. In: Lew EA, Gajewski J (eds). Medical Risks: trends in mortality by age and time elapsed. New York: Praeger, 1990; 8–60 to 8–61.Google Scholar
  200. 200.
    Brackenridge RDC. Respiratory system diseases. In: Lew EA, Gajewski J (eds). Medical Risks: trends in mortality by age and time elapsed. New York: Praeger, 1990; 8–56 to 8–57.Google Scholar
  201. 201.
    Donowitz GR, Mandell GL. Acute pneumona. In: Mandell GL, Bennet JE, Dolin R (eds). Principles and Practice of Infectious Disease. 4th edn. New York: Churchill Livingstone, 1995; 629.Google Scholar
  202. 202.
    Finegold S. Lung abscess. In: Mandell GL, Bennet JE, Dolin R (eds). Principles and Practice of Infectious Disease. 4th edn. New York: Churchill Livingstone, 1995; 646.Google Scholar
  203. 203.
    Bryant RE. Pleural effusion and empyema. In: Mandell GL, Bennet JE, Dolin R (eds). Principles and Practice of Infectious Disease 4th edn. New York: Churchill Livingstone, 1995; 640.Google Scholar
  204. 204.
    Enarson DA, Murray JF. Global epidemiology of tuberculosis. In: Rom WM, Garay SM (eds). Tuberculosis. Boston: Little, Brown and Co, 1996; 57–75.Google Scholar
  205. 205.
    American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359–75.CrossRefGoogle Scholar
  206. 206.
    Colice GL. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors. Arch Intern Med 1990; 150: 2517–22.PubMedCrossRefGoogle Scholar
  207. 207.
    El-Haddad, Alavi A, Mavi A, Bural G, Zhuang H: Normal variants in [18F]-fluorodeoxyglucose PET imaging. Radiologic Clinics of North America 2004; 42(6): 1063–81.PubMedCrossRefGoogle Scholar
  208. 208.
    Hartman TE: Radiologic Evaluation of the Solitary Pulmonary Nodule. Radiologic Clinics of North America 2005; 43: 459–465.Google Scholar

Copyright information

© Palgrave Macmillan, a division of Macmillan Publishers Limited 2006

Authors and Affiliations

  • Martin L Engman
  • Rodney C Richie

There are no affiliations available

Personalised recommendations